(January 23, 2024, 2:15 PM EST) -- RENO, Nev. — A biopharmaceutical company misled investors by failing to disclose that its ability to test a drug planned to treat Alzheimer’s disease was severely impacted by the ongoing COVID-19 pandemic, an investor says in a putative class complaint filed in a federal court in Nevada....